WHO ARE WE?
AXIM is a preclinical-stage biopharmaceutical and diagnostic company pioneering the discovery and development of first-in-class targeted small molecule and monoclonal antibody therapies that disrupt extracellular matrix formation to block tumor cell growth and metastasis.
AXIM acquired Sapphire Biotech in early 2020 in order to develop and commercialize a unique therapeutic approach designed to disrupt cancer growth and block metastatic spread. Sapphire, now part of AXIM, has acquired an exclusive license to the technology around SBI-183, an anti-metastatic compound developed by Dr. Douglas Lake at Mayo Clinic and Arizona State University. Dr. Douglas Lake is a co-founder of Sapphire Biotech. An important part of the License Agreement provided for the granting of equity to Skysong Innovations, LLC, the licensing agent for Mayo/ASU.
As AXIM Biotech is a pioneer in the research and development of diagnostic tools for the early screening of cancer cells, our researchers have been able to quickly adapt our existing research and products currently under development to create a diagnostic tool that screens for COVID-19 neutralizing antibodies. The need for such an instrument is great as the pandemic continues to plauge the worldwide healthcare landscape.
Some references to the Company relate to Sapphire and events occurring prior to the acquisition by AXIM.
AXIM’s mission is to improve global cancer care through the development of novel Therapeutics for inhibiting metastatic cancer growth, and Diagnostics for early cancer detection, response to treatment, and recurrence monitoring. AXIM aspires to be the leader in QSOX1-targeted metastatic cancer therapies and has undertaken the development of a potent QSOX1 inhibitor to be used as a platform drug for a variety of indications.
The Company has been studying the enzyme Quiescin Sulfhydryl Oxidase 1 (QSOX1) and its over-expression by tumor cells. QSOX1 has been shown to be involved with invasion and metastasis. Dr. Douglas Lake, has reported that a small molecule SBI-183, inhibited the enzymatic activity of QSOX1 and suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo. The Company has identified SPX-1009, an analog of SBI-183, with tenfold increased potency, and is testing SPX-1009 for suppression of cancer invasion and metastasis in vitro and in vivo.
HOW WE ARE DIFFERENT
Liquid biopsy refers to the process of testing the blood for the presence of a disease biomarker. Most so-called “Liquid Biopsy” companies test blood for circulating tumor cells (CTCs) and DNA sequences. The disease biomarker we test for is an enzyme.
AXIM is the first to discover the over-experssion of QSOX1 as a biomarker for cancer in blood. We have filed a patent application claiming many discoveries related to QSOX1, including a rapid diagnostic test which we have developed into a lateral flow device capable of measuring levels of QSOX1. The Company’s equivalent of a liquid biopsy test is a non-invasive, rapid blood test that will measure QSOX1 over-expression. The Company seeks to prove that measuring QSOX1 over-expression even before the tumor is formed, will enable detection of cancer at an earlier stage than liquid biopsy companies whose tests detect the CTC’s and DNA, usually after the tumor is formed and is shedding cells.